Company Filing History:
Years Active: 1997-2002
Title: The Innovative Contributions of Morris Reichlin
Introduction
Morris Reichlin is a notable inventor based in Oklahoma City, OK (US). He has made significant contributions to the field of medical research, particularly in the treatment of systemic lupus erythematosus (SLE). With a total of 3 patents, his work has the potential to improve the lives of many patients suffering from this autoimmune disease.
Latest Patents
Reichlin's latest patents include a method for the treatment of SLE. This innovative approach involves the use of anti-ID antibodies to dsDNA to block the harmful anti-dsDNA antibodies and/or eliminate the B cells that produce these antibodies. His research demonstrates that anti-dsDNA antibodies are cross-reactive with ribosomal protein S1, which suppresses protein synthesis by inhibiting mRNA translation initiation. Additionally, he has developed assays for the pathogenicity of anti-DNA antibodies, which can prognosticate patients at risk of developing nephritis. These assays screen patient serum for anti-dsDNA antibodies that cross-react with A and D SnRNP proteins, utilizing peptides or antigens to induce tolerance.
Career Highlights
Morris Reichlin is affiliated with the Oklahoma Medical Research Foundation, where he conducts his research. His work has garnered attention for its innovative approaches to treating and understanding lupus. His contributions to the field have been recognized through his patents and ongoing research efforts.
Collaborations
Reichlin collaborates with esteemed colleagues such as Eugen Koren and Wei Zhang. Their combined expertise enhances the research and development of therapeutic solutions for autoimmune diseases.
Conclusion
Morris Reichlin's innovative work in the treatment of systemic lupus erythematosus showcases his dedication to advancing medical research. His patents and collaborations reflect a commitment to improving patient outcomes in the field of autoimmune diseases.